Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
08:57pm, Tuesday, 24'th Feb 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) What: Securitie
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: R
New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:11am, Tuesday, 24'th Feb 2026
LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
09:11am, Tuesday, 24'th Feb 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Ultragenyx Pharmaceutical Inc.(RARE) Shareholders
09:00am, Tuesday, 24'th Feb 2026
NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE durin
Ultragenyx to Participate at Investor Conferences in March
04:30pm, Monday, 23'rd Feb 2026
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3
Ultragenyx Pharmaceutical Inc. Securities Class Action Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law
09:31am, Monday, 23'rd Feb 2026
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmace
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
04:08am, Monday, 23'rd Feb 2026
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for viol
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:06am, Monday, 23'rd Feb 2026
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("
New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) b
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
